Navigation Links
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A.

Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene resulting in a deficiency of factor VIII protein. Lentigen and Expression Therapeutics will develop two types of treatments for Hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.

"Hemophilia A is a serious disease, affecting about one in 10,000 people worldwide," explained Dr. Boro Dropulic, President and Chief Scientific Officer of Lentigen. "The two therapeutic approaches leverage Lentigen's technology in two important areas: protein expression and cell therapy. Factor VIII is a difficult protein to manufacture but Lentigen's protein expression technology will permit the production of a novel human factor VIII protein at levels highly favorable for commercialization. Secondly, Expression Therapeutics' proprietary factor VIII will be used in a novel stem cell therapy for Hemophilia A that aims to restore the clotting capability of patients suffering from this debilitating disease.

"The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A. By combining our high expression factor VIII technology with Lentigen's protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace," stated Dr. Trent Spencer, President of Expression Therapeutics.

Tim Ravenscroft, Lentigen's Chief Executive Officer, commented, "We are excited to be working with Expression Therapeutics on factor VIII treatments. The projects are consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit

About Expression Therapeutics

Expression Therapeutics, LLC is a privately owned biotechnology company in Atlanta focused on the development of products that will improve the standard of treatment for individuals with hemophilia A. The high-expression factor VIII technology developed by Expression Therapeutics can be used in the development of both protein replacement and cell therapy-based therapeutics. For further information, visit

    Lentigen Media Contacts:
    Richard Lewis Communications, Inc. (212) 827-0020
    Gregory Tiberend,
    Cecelia Heer,

    Expression Therapeutics Media Contacts:
    Gabriela Denning, (678) 278-1140
    Keith Kerstann,

SOURCE Lentigen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
2. Lentigen Corporation Announces Relocation to New Facility
3. Lentigen Appoints Jim Meade as Vice President of Corporate Development
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
8. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
9. VIRxSYS and Lentigen Announce Litigation Settlement
10. New technique allows simultaneous tracking of gene expression and movement
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
Breaking Biology News(10 mins):